Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 4/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | TLR4 | O00206 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30121243 | 0.90 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1KDM1A | |
| SCHEMBL31020422 | 0.89 | ALDH1A1 (0.62) | ALDH1A1GAATSHREPHX1KDM1A | |
| Hydrochloric Acid SCHEMBL30121142 | 0.88 | ALDH1A1 (0.61) | ALDH1A1GAATSHREPHX1KDM1A | |
| SCHEMBL3948461 | 0.88 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1KDM1A | |
| SCHEMBL3948456 | 0.88 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1KDM1A | |
| SCHEMBL381922 | 0.88 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1KDM1A | |
| SCHEMBL28001597 | 0.87 | ALDH1A1 (0.67) | ALDH1A1GAATSHREPHX1KDM1A | |
| SCHEMBL25568205 | 0.87 | ALDH1A1 (0.67) | ALDH1A1GAATSHREPHX1KDM1A | |
| SCHEMBL30121373 | 0.87 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1KDM1A | |
| Hydrochloric Acid SCHEMBL28135182 | 0.86 | ALDH1A1 (0.83) | ALDH1A1GAATSHREPHX1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2154970-B1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-8642633-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8404682-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2012-02-09 | — | — | US | disclosed |
| US-8013003-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
| EP-2154970-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008143963-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN2A, GRIN2B, SLC18A2 | ALDH1A1 1891/4885GAA 256/4885TSHR 2042/4885 |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | DRD2, DRD3, GAP43 | ALDH1A1 1189/4885GAA 481/4885TSHR 1195/4885 |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | DRD2, DRD3, GAP43 | ALDH1A1 1189/4885GAA 481/4885TSHR 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.